Dual chimeric antigen receptor gene modified immune cell based on CD19 and CD22 and application thereof

A technology of chimeric antigen receptors and immune cells, which is applied to genetically modified cells, cells modified by introducing foreign genetic material, animal cells, etc., can solve the problems of unsatisfactory long-term effects, so as to avoid escape and enhance long-term immunity. Strong immune effect and anti-tumor effect

Active Publication Date: 2019-03-26
BEIJING MEIKANG JIMIAN BIOTECH CO LTD
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In view of the unsatisfactory long-term effect of a single target in the current CAR-T technology treatment of tumors, and the fact that the tumor microenvironment affects the therapeutic effect of CAR-T technology, the present invention provides a dual chimeric antigen receptor gene based on CD19 and CD22 Modified immune cells and their application, the present invention is for the first time combined with dual tumor targets of CD19 and CD22, has the characteristics of strong specificity and high targeting, can effectively improve and prolong the effect of CART treatment, and targets surface antigens CD19 and CD22 Positive leukemia or B-cell lymphoma has a better therapeutic effect, effectively avoiding single-target off-target escape

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual chimeric antigen receptor gene modified immune cell based on CD19 and CD22 and application thereof
  • Dual chimeric antigen receptor gene modified immune cell based on CD19 and CD22 and application thereof
  • Dual chimeric antigen receptor gene modified immune cell based on CD19 and CD22 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1 Construction of Chimeric Antigen Receptor

[0084] (1) Synthesize Secretory signal peptide, CD19 or CD22 antigen-binding domain, CD8α and / or CD28 transmembrane domain, CD28 signaling domain, CD27 signaling domain, CD3ζ signaling domain, 2A sequence and Caspase 9 domains, such as figure 1 As shown, namely Secretory-CD19 scFv-CD28-CD27-CD3ζ-2A-FBKP.Casp9 and Secretory-CD22 scFv-CD28-CD27-CD3ζ-2A-FBKP.Casp9; the specific sequences are as follows:

[0085] The nucleotide sequence of Secretory-CD19 scFv-CD28-CD27-CD3ζ-2A-FBKP.Casp9 is shown in SEQ ID NO.5.

[0086] The nucleotide sequence of Secretory-CD22 scFv-CD28-CD27-CD3ζ-2A-FBKP.Casp9 is shown in SEQ ID NO.7.

Embodiment 2

[0087] Example 2 lentiviral packaging

[0088] (1) Use 293T cells and culture for 17-18 hours;

[0089] (2) Add fresh DMEM containing 10% FBS;

[0090] (3) Add the following reagents to a sterile centrifuge tube: Take DMEM from each well, add helper DNA mix (pNHP, pHEF-VSV-G) and pTYF DNA vector, and vortex;

[0091] (4) Add Superfect or any transgenic material to the centrifuge tube, and let stand at room temperature for 7-10 minutes;

[0092] (5) Add the DNA-Superfect mixture in the centrifuge tube to each cultured cell drop by drop, and vortex to mix well;

[0093] (6) 37°C 3% CO 2 Cultivate in the incubator for 4-5 hours;

[0094] (7) Suck away the culture fluid of the culture medium, wash the culture medium with 293 cell culture fluid, and add the culture fluid to continue culturing;

[0095] (8) Return the culture medium to 3% CO 2 Culture overnight in an incubator, and observe the transfection efficiency with a fluorescence microscope the next morning.

Embodiment 3

[0096] Example 3 Purification and Concentration of Lentivirus

[0097] 1) Virus purification

[0098] Remove cell debris by centrifugation at 1000g for 5 minutes to obtain virus supernatant, filter the virus supernatant with a 0.45 micron low protein binding filter, divide the virus into aliquots, and store at -80°C;

[0099] Typically, transfected cells can produce 10 6 to 10 7 Lentiviral vectors for titration of transducing units.

[0100] 2) Concentrate the lentiviral vector with a Centricon or similar filter

[0101] (1) Add virus supernatant to Centricon or similar filter tube, then centrifuge at 2500g for 30 minutes;

[0102] (2) Shake the filter tube, then centrifuge at 400g for 2 minutes, and collect the concentrated virus into the collection cup. Finally, pool the virus in all tubes into one centrifuge tube.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a dual chimeric antigen receptor gene modified immune cell based on CD19 and CD22 and application thereof. The dual chimeric antigen receptor comprises a chimeric antigen receptor CD19 and a chimeric antigen receptor CD22. The chimeric antigen receptor is composed of an antigen binding domain, a transmembrane domain, a co-stimulation signal transduction region and a CD3 zeta signal transduction domain, and an inducible suicide fusion domain, which are connected in series. The chimeric antigen receptor provided by the invention can be used for specifically identifying tumor surface antigens CD19 and CD22; and compared with the utilization of other single chimeric antigen receptor T cells, the combined utilization of two types of antigen targeting CAR-T cells has a better treatment effect and CD19 escaping is not easy to occur, so that diseases are easier to alleviate.

Description

technical field [0001] The present invention relates to the field of tumor cell immunotherapy, in particular to a CD19 and CD22-based dual chimeric antigen receptor gene-modified immune cell and its application, specifically a chimeric antigen based on tumor-specific targets CD19 and CD22 Construction method of receptor T (CAR-T) cell technology and its application in anti-tumor therapy. Background technique [0002] With the development of tumor immunology theory and clinical technology, chimeric antigen receptor T-cell immunotherapy (CAR-T) has become one of the most promising tumor immunotherapy. Generally, a chimeric antigen receptor CAR consists of a tumor-associated antigen-binding region, an extracellular hinge region, a transmembrane region, and an intracellular signal transduction region. Usually, CAR contains the single chain fragment variable (single chain fragment variable, scFv) region of the antibody or the binding domain specific to the tumor associated antig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10C12N15/867C12N7/01C07K16/28C07K16/30A61K35/17A61P35/00A61P35/02
CPCA61P35/00A61P35/02A61K35/17C12N7/00C12N15/86C07K14/7051C07K16/2803C07K16/3061C12N2510/00C12N2740/15021C12N2740/15043C07K2319/33C07K2319/02C07K2319/03C07K14/70517C07K14/70521C07K14/70575C07K14/70578C12N9/6472C12Y304/22062A61K2039/5156C07K2317/622A61K39/001112A61K39/001113A61K2039/5158C12N5/0636C12N2740/16043A61K38/00
Inventor 李俊芳
Owner BEIJING MEIKANG JIMIAN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap